Meyer Handelman Co. lessened its holdings in Pfizer Inc. (NYSE:PFE – Free Report) by 2.6% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 1,098,861 shares of the biopharmaceutical company’s stock after selling 28,979 shares during the period. Meyer Handelman Co.’s holdings in Pfizer were worth $26,461,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently modified their holdings of PFE. Vermillion Wealth Management Inc. lifted its position in Pfizer by 19.4% in the first quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company’s stock valued at $66,000 after buying an additional 382 shares during the last quarter. Eagle Capital Management LLC increased its position in shares of Pfizer by 0.3% during the first quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company’s stock valued at $3,554,000 after acquiring an additional 390 shares during the last quarter. Delta Financial Advisors LLC increased its position in shares of Pfizer by 1.6% during the first quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company’s stock valued at $709,000 after acquiring an additional 398 shares during the last quarter. Pines Wealth Management LLC raised its position in Pfizer by 4.4% in the fourth quarter. Pines Wealth Management LLC now owns 9,430 shares of the biopharmaceutical company’s stock valued at $235,000 after purchasing an additional 400 shares during the period. Finally, Mount Vernon Associates Inc. MD lifted its stake in Pfizer by 1.0% during the first quarter. Mount Vernon Associates Inc. MD now owns 41,919 shares of the biopharmaceutical company’s stock worth $1,177,000 after purchasing an additional 400 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of analysts have issued reports on the stock. Citigroup boosted their price target on shares of Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 29th. JPMorgan Chase & Co. cut their target price on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 8th. Guggenheim dropped their price target on shares of Pfizer from $35.00 to $31.00 and set a “buy” rating for the company in a research note on Friday, August 7th. Weiss Ratings reiterated a “hold (c)” rating on shares of Pfizer in a report on Monday, August 3rd. Finally, Royal Bank Of Canada upgraded Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price target on the stock in a report on Tuesday, June 9th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Pfizer currently has an average rating of “Hold” and a consensus target price of $28.28.
Pfizer Trading Up 0.3%
PFE opened at $26.88 on Tuesday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. Pfizer Inc. has a one year low of $23.58 and a one year high of $28.75. The company has a market cap of $153.21 billion, a P/E ratio of 35.37 and a beta of 0.34. The business’s 50-day simple moving average is $25.15 and its 200-day simple moving average is $26.20.
Pfizer (NYSE:PFE – Get Free Report) last issued its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.68 by $0.09. The business had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities research analysts expect that Pfizer Inc. will post 2.98 EPS for the current fiscal year.
Pfizer Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.4%. Pfizer’s payout ratio is 226.32%.
Pfizer Profile
Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.
Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.
Further Reading
- Five stocks we like better than Pfizer
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
